SEC 13F Intelligence

Managers / Q4 2025 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$171M
Q4 2025
Positions
68
Filings on Record
39
2019–present window
Filed
Feb 13, 2026
original filing

Summary

Birchview Capital, LP reported $171M in U.S.-listed holdings across 68 positions for Q4 2025.

Its largest position, KLAC, represents 15.6% of the portfolio.

Compared with Q3 2025, the fund opened 11 new positions and exited 12.

Portfolio Metrics

Turnover
+13.7%
vs prior filed quarter
Top-10 Concentration
+54.6%
share of reported value
Largest Position
+15.6%
Kla Corporation
New / Exited
11 / 12
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 87.5%Other: 6.9%ADR: 5.6%
  • Common Stock · 87.5% · $150M
  • Other · 6.9% · $12M
  • ADR · 5.6% · $10M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
LRCXLAM RESEARCH CORPORATIONNEW+40.3K40.3K+$7M$7M
VERAVERA THERAPEUTICS INCNEW+44.0K44.0K+$2M$2M
VSTMVERASTEM INCNEW+150.0K150.0K+$1M$1M
TXG10X GENOMICS INCNEW+59.0K59.0K+$962,290$962,290
ILMNILLUMINA INCNEW+6.0K6.0K+$786,960$786,960
BIOHAVEN LTDNEW+59.4K59.4K+$670,231$670,231
LUNGPULMONX CORPNEW+250.6K250.6K+$553,766$553,766
RAPTRAPT THERAPEUTICS INCNEW+15.0K15.0K+$508,050$508,050

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2025

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1KLACKLA CORPORATIONhistory →COM NEW15.57%$27M21.9K
2BMYBRISTOL-MYERS SQUIBB COhistory →COM9.56%$16M302.8K
3CMPXCOMPASS THERAPEUTICS INChistory →COM5.01%$9M1.59M
4STOKSTOKE THERAPEUTICS INChistory →COM4.83%$8M260.0K
5LRCXLAM RESEARCH CORPORATIONhistory →COM NEW4.04%$7M40.3K
6OLMAOLEMA PHARMACEUTICALS INChistory →COM3.94%$7M269.0K
7GPCRSTRUCTURE THERAPEUTICS INChistory →SPONS ADR3.66%$6M90.0K
8PTGXPROTAGONIST THERAPEUTICS INChistory →COM2.81%$5M55.0K
9ACADACADIA PHARMACEUTICALS INChistory →COM2.67%$5M171.0K
10OVVOVINTIV INChistory →COM2.47%$4M107.5K
11PROTHENA CORP PLCSHS2.47%$4M441.0K
12SLDBSOLID BIOSCIENCES INChistory →COM NEW2.33%$4M706.0K
13NBIXNEUROCRINE BIOSCIENCES INChistory →COM2.26%$4M27.2K
14AM6AMICUS THERAPEUTICS INChistory →COM2.11%$4M253.0K
15BCYCBICYCLE THERAPEUTICS PLChistory →SPONSORED ADS1.92%$3M462.7K
16PHATPHATHOM PHARMACEUTICALS INChistory →COM1.89%$3M195.0K
17CSTLCASTLE BIOSCIENCES INChistory →COM1.84%$3M80.6K
18NTLAINTELLIA THERAPEUTICS INChistory →COM1.66%$3M315.4K
19IMNMIMMUNOME INChistory →COM1.63%$3M130.0K
20HTDCORCEPT THERAPEUTICS INChistory →COM1.37%$2M67.2K
21VERAVERA THERAPEUTICS INChistory →CL A1.30%$2M44.0K
22QDEL*QUIDELORTHO CORPhistory →COM1.21%$2M72.5K
23NOVOCURE LTDORD SHS1.15%$2M152.1K
24BIODESIX INCCOM1.14%$2M286.8K
25CYTKCYTOKINETICS INChistory →COM1.12%$2M30.0K
26PHRPHREESIA INChistory →COM1.10%$2M110.7K
27EQTEQT CORPORATIONhistory →COM1.09%$2M34.6K
28HROWHARROW HEALTH INCCOM0.98%$2M34.0K
29TVTXTRAVERE THERAPEUTICS INCCOM0.96%$2M43.0K
30FHTXFOGHORN THERAPEUTICS INCCOM0.89%$2M281.7K
31UTHUNITED THERAPEUTICS CORPCOM0.86%$1M3.0K
32RAREULTRAGENYX PHARMACEUTICAL INCCOM0.83%$1M62.0K
33ALKERMES PLCSHS0.82%$1M50.0K
34NKTRNEKTAR THERAPEUTICSCOM0.77%$1M31.0K
35APGEAPOGEE THERAPEUTICS INCCOM0.71%$1M16.0K
36VSTMVERASTEM INCCOM NEW0.68%$1M150.0K
37AXSMAXSOME THERAPEUTICS INCCOM0.65%$1M6.1K
38MASI*MASIMO CORPCOM0.63%$1M8.3K
39TXG10X GENOMICS INCCOM0.56%$962,29059.0K
40XENEXENON PHARMACEUTICALS INCCOM0.55%$941,22021.0K
41PACBPACIFIC BIOSCIENCES OF CALIFORNIA INCCOM0.55%$935,000500.0K
424XC1KALVISTA PHARMACEUTICALS INCCOM0.54%$920,55057.0K
43FCXFREEPORT-MCMORAN CL-BCL-B0.54%$916,57718.0K
44VTYXUSDVENTYX BIOSCIENCES INCCOM0.53%$910,468100.8K
45PHARVARIS N VCOM0.48%$828,25429.8K
46ILMNILLUMINA INCCOM0.46%$786,9606.0K
47UNIQURE NVSHS0.43%$736,78130.8K
48HALOHALOZYME THERAPEUTICS INCCOM0.40%$679,73010.1K
49BIOHAVEN LTDCOM0.39%$670,23159.4K
50BBIOBRIDGEBIO PHARMA INCCOM0.39%$664,5458.7K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.